Boehringer terminates Alzheimer’s candidate after Phase 2 failure
pharmafile | February 12, 2018 | News story | Research and Development, Sales and Marketing | Alzheimer’s, Boehringer Ingelheim, dementia, pharma
Boehringer Ingelheim has announced its intention to halt development of its candidate BI 409306 in the treatment of Alzheimer’s after it failed to hit its primary endpoints in Phase 2 studies.
In the trials of 457 patients with cognitive impairment as a result of Alzheimer’s disease, the drug failed to show superiority in improving cognition compared to placebo. The studies were part of a greater programme investigating compounds which target malfunctioning of glutamatergic brain circuits. The company said that full details from the studies would be presented at the Alzheimer’s Association International Conference later this year following a full review of the data.
With the Alzheimer’s trial terminated, Boehringer indicated that it will investigate the therapy’s efficacy in schizophrenia instead, focusing on the prevention of the first psychotic episode in patient with the condition. The company will still conduct research into the field of dementia through its GlyT1 inhibitor BI 425809.
“This is what research is about: disappointments are a daily experience in science, but even these clinical trial results will add to the understanding of brain function and contribute to future progress in this area,” commented Jan Poth, Therapeutic Area Head of CNS diseases at Boehringer Ingelheim.
Stephane Pollentier, Head of Medicine, Therapeutic Area CNS, added: “Starting from our systematic neurobiological approach to CNS research, we will continue to build innovative approaches in our clinical trials and help advance the field in collaboration with the wider scientific community. We won’t rest.”
Matt Fellows
Related Content
Well Pharmacy and Alzheimer’s Society launch dementia partnership
Well Pharmacy has announced a partnership with Alzheimer’s Society aimed at improving support for people …
Vesper Bio reports positive topline results for dementia candidate
Vesper Bio, a clinical-stage biotech developing novel oral therapies for neurodegenerative and neuropsychiatric disorders, has …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
